Michael Gschwantler
Research Subjects
Michael Gschwantler has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Schwarz
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria
10 shared publications - Thomas Reiberger
Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
9 shared publications - Peter Ferenci
Division of Gastroenterology and Hepatology, Department of Internal Medicine III Medical University of Vienna Vienna Austria
6 shared publications - Angelika Schütz
Suchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria
5 shared publications - Hans Haltmayer
Suchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria
5 shared publications - Michael Schwarz
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
5 shared publications
Latest Publications
- Open Access
- 4 October 2025
- Published by Elsevier in Journal of Virus Eradication
- Vol. 11 (4) , 100611
A liberalized approach to directly observed therapy for HCV retains excellent cure rates among PWID in Vienna
- 4 October 2025
- Published by Elsevier in Journal of Virus Eradication
- Vol. 11 (4) , 100611
Open AccessA liberalized approach to directly observed therapy for HCV retains excellent cure rates among PWID in Vienna
- 11 August 2023
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 30 (6)
Diaphragmatic perforation as a result of cystic echinococcosis in an HIV-positive migrant
A 51-year-old female Bulgarian migrant living with HIV presented with abdominal pain, cough, and elevated inflammation parameters. Computed tomography revealed extensive cystic structures perforating from the liver through the diaphragm into the right lung, where they showed bronchial communication. The finding corresponded to a transitional cyst stage of cystic echinococcosis.
- 11 August 2023
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 30 (6)
Diaphragmatic perforation as a result of cystic echinococcosis in an HIV-positive migrant
A 51-year-old female Bulgarian migrant living with HIV presented with abdominal pain, cough, and elevated inflammation parameters. Computed tomography revealed extensive cystic structures perforating from the liver through the diaphragm into the right lung, where they showed bronchial communication. The finding corresponded to a transitional cyst stage of cystic echinococcosis.
- Open Access
- 27 July 2023
- Published by Elsevier in Journal of Virus Eradication
- Vol. 9 (3) , 100338
CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
- 27 July 2023
- Published by Elsevier in Journal of Virus Eradication
- Vol. 9 (3) , 100338
Open AccessCHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
- 5 May 2023
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 135 (11-12) , 311-315
Diffuse idiopathic skeletal hyperostosis as a cause for dysphagia in a patient with ankylosing spondylitis
Summary Background Diffuse idiopathic skeletal hyperostosis (DISH) is characterized by ankylosing spinal alterations which are often asymptomatic but may typically cause back pain and spinal stiffness. Presence of DISH may complicate spinal trauma and lead to unstable fractures requiring surgical intervention. Treatment options include physical activity, symptomatic treatment, local heat application, and optimization of metabolic comorbidities. Case A multimorbid older patient was admitted to the gastroenterological ward for the investigation of progressive dysphagia and weight loss. Gastroscopy revealed a dorsal impression of the esophagus at 25 cm from the incisor. Clinical work-up including computed tomography (CT) and magnetic resonance imaging (MRI) ruled out malignancy but showed ankylosing spondylophytes and non-recent fractures of vertebrae C5–C7, compatible with DISH of the cervicothoracic spine as a cause for the esophageal impression. Notably, imaging diagnostics showed ankylosing spine alterations extending to the lumbar spine and both sacroiliac joints, suggestive of ankylosing spondylitis (AS). Typical imaging characteristics, a history of psoriasis, and positive HLA*B27 status supported the diagnosis of underlying AS in this patient with dysphagia as an unusual primary symptom of DISH. Additionally, pulmonary alterations compatible with a usual interstitial pneumonia (UIP)-like pattern were seen on lung CT. Conclusion Overlaps among AS, DISH and pulmonary abnormalities including UIP have been described previously; however, they represent unexpected findings in this older patient. This case underlines the importance of interdisciplinary collaboration and consideration of DISH as a differential diagnosis in patients with atypical symptoms.
- 5 May 2023
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 135 (11-12) , 311-315
Diffuse idiopathic skeletal hyperostosis as a cause for dysphagia in a patient with ankylosing spondylitis
Summary Background Diffuse idiopathic skeletal hyperostosis (DISH) is characterized by ankylosing spinal alterations which are often asymptomatic but may typically cause back pain and spinal stiffness. Presence of DISH may complicate spinal trauma and lead to unstable fractures requiring surgical intervention. Treatment options include physical activity, symptomatic treatment, local heat application, and optimization of metabolic comorbidities. Case A multimorbid older patient was admitted to the gastroenterological ward for the investigation of progressive dysphagia and weight loss. Gastroscopy revealed a dorsal impression of the esophagus at 25 cm from the incisor. Clinical work-up including computed tomography (CT) and magnetic resonance imaging (MRI) ruled out malignancy but showed ankylosing spondylophytes and non-recent fractures of vertebrae C5–C7, compatible with DISH of the cervicothoracic spine as a cause for the esophageal impression. Notably, imaging diagnostics showed ankylosing spine alterations extending to the lumbar spine and both sacroiliac joints, suggestive of ankylosing spondylitis (AS). Typical imaging characteristics, a history of psoriasis, and positive HLA*B27 status supported the diagnosis of underlying AS in this patient with dysphagia as an unusual primary symptom of DISH. Additionally, pulmonary alterations compatible with a usual interstitial pneumonia (UIP)-like pattern were seen on lung CT. Conclusion Overlaps among AS, DISH and pulmonary abnormalities including UIP have been described previously; however, they represent unexpected findings in this older patient. This case underlines the importance of interdisciplinary collaboration and consideration of DISH as a differential diagnosis in patients with atypical symptoms.
- Open Access
- 1 March 2023
- Published by Elsevier in Journal of Virus Eradication
- Vol. 9 (1) , 100319
Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy
- 1 March 2023
- Published by Elsevier in Journal of Virus Eradication
- Vol. 9 (1) , 100319
Open AccessCombining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy
- Open Access
- 27 January 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 975
Association of Interleukin-32 and Interleukin-34 with Cardiovascular Disease and Short-Term Mortality in COVID-19
Background: Excess cardiovascular (CV) morbidity and mortality has been observed in patients with COVID-19. Both interleukin-32 (IL-32) and interleukin-34 (IL-34) have been hypothesized to contribute to CV involvement in COVID-19. Methods: This prospective, observational study of patients with laboratory-confirmed COVID-19 infection was conducted from 6 June to 22 December 2020 in a tertiary care hospital in Vienna, Austria. IL-32 and IL-34 levels on admission were collected and tested for their association with CV disease and short-term mortality in patients with COVID-19. CV disease was defined by the presence of coronary artery disease, heart failure, stroke or atrial fibrillation and patients were stratified by CV disease burden. Results: A total of 245 eligible patients with COVID-19 were included, of whom 37 (15.1%) reached the primary endpoint of 28-day mortality. Of the total sample, 161 had no CV disease (65.7%), 69 had one or two CV diseases (28.2%) and 15 patients had ≥three CV diseases (6.1%). Median levels of IL-32 and IL-34 at admission were comparable across the three groups of CV disease burden. IL-32 and IL-34 failed to predict mortality upon both univariable and multivariable Cox regression analysis. The two CV disease groups, however, had a significantly higher risk of mortality within 28 days (one or two CV diseases: crude HR 4.085 (95% CI, 1.913–8.725), p < 0.001 and ≥three CV diseases: crude HR 13.173 (95% CI, 5.425–31.985), p < 0.001). This association persisted for those with ≥three CV diseases after adjustment for age, gender and CV risk factors (adjusted HR 3.942 (95% CI, 1.288–12.068), p = 0.016). Conclusion: In our study population of hospitalized patients with COVID-19, IL-32 and IL-34 did not show any associations with CV disease or 28-day mortality in the context of COVID-19. Patients with multiple CV diseases, however, had a significantly increased risk of short-term mortality.
- 27 January 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 975
Open AccessAssociation of Interleukin-32 and Interleukin-34 with Cardiovascular Disease and Short-Term Mortality in COVID-19
Background: Excess cardiovascular (CV) morbidity and mortality has been observed in patients with COVID-19. Both interleukin-32 (IL-32) and interleukin-34 (IL-34) have been hypothesized to contribute to CV involvement in COVID-19. Methods: This prospective, observational study of patients with laboratory-confirmed COVID-19 infection was conducted from 6 June to 22 December 2020 in a tertiary care hospital in Vienna, Austria. IL-32 and IL-34 levels on admission were collected and tested for their association with CV disease and short-term mortality in patients with COVID-19. CV disease was defined by the presence of coronary artery disease, heart failure, stroke or atrial fibrillation and patients were stratified by CV disease burden. Results: A total of 245 eligible patients with COVID-19 were included, of whom 37 (15.1%) reached the primary endpoint of 28-day mortality. Of the total sample, 161 had no CV disease (65.7%), 69 had one or two CV diseases (28.2%) and 15 patients had ≥three CV diseases (6.1%). Median levels of IL-32 and IL-34 at admission were comparable across the three groups of CV disease burden. IL-32 and IL-34 failed to predict mortality upon both univariable and multivariable Cox regression analysis. The two CV disease groups, however, had a significantly higher risk of mortality within 28 days (one or two CV diseases: crude HR 4.085 (95% CI, 1.913–8.725), p < 0.001 and ≥three CV diseases: crude HR 13.173 (95% CI, 5.425–31.985), p < 0.001). This association persisted for those with ≥three CV diseases after adjustment for age, gender and CV risk factors (adjusted HR 3.942 (95% CI, 1.288–12.068), p = 0.016). Conclusion: In our study population of hospitalized patients with COVID-19, IL-32 and IL-34 did not show any associations with CV disease or 28-day mortality in the context of COVID-19. Patients with multiple CV diseases, however, had a significantly increased risk of short-term mortality.
- 24 November 2022
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 22 (12) , 1769
Isolated peritoneal involvement as a primary manifestation of cystic echinococcosis
- 24 November 2022
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 22 (12) , 1769
Isolated peritoneal involvement as a primary manifestation of cystic echinococcosis
- Open Access
- 3 November 2022
- Published by Elsevier in SSRN Electronic Journal
Combining Treatment for Chronic Hepatitis C with Opioid Agonist Therapy is an Effective Microelimination Strategy for People Who Inject Drugs with High Risk of Non-Adherence to Antiviral Therapy
Background & Aims: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation. To overcome this, we combined ongoing opioid agonist therapy (OAT) with direct-acting antivirals (DAA) in a directly-observed therapy (DOT) setting. Method: From September 2014 until January 2021 PWIDs at high risk for non-adherence to DAA therapy were included in this microelimination project. PWIDs received HCV treatment alongside their OAT under supervision of healthcare workers in a pharmacy or low-threshold facility. Results: In total, 522 HCV-RNA-positive PWIDs (400 men, 76.6%; median age: 38 years [IQR 12], HIV: 4.4%; HBV: 1.3%) were included. Of these, 308/491 patients (62.7%) reported ongoing IDU (intravenous drug use). Following the concept of DOT, adherence to DAA treatment was excellent (missed appointments: 90/25,792, 0.4%). Forty-one (7.9%) patients were lost to follow-up. Two (0.4%) patients died due to reasons unrelated to DAA treatment. SVR12 was achieved in 457/461 (99.1%; 95% CI: 98.3-100.0%) patients, while only 4/461 (0.9%) patients showed treatment failure (modified intention-to-treat, mITT). Over a median follow-up of 24 (IQR 27) weeks, reinfections were observed in 27/457 (5.9%) patients. Conclusions: Coupling DAA treatment to OAT in a DOT setting resulted in SVR12 rates greater than 99% in PWIDs at high risk for non-adherence to therapy despite high rates of IDU. Importantly, only 7.9% of the patients were lost to follow-up, but finished DAA therapy. Competing Intrerest Statement: Michael Schwarz, Austria (schwarz.medizin@gmail.com): received speaking honoraria from BMS and travel support from BMS, AbbVie, Gilead, and MSD. - Caroline Schwarz, Austria (schwarz.caroline1990@gmail.com): received travel support from Gilead, Abbvie, and Gebro; speaking honoraria from Abbvie and Gilead; and served as a consultant for Gilead. Angelika Schütz, Austria (angelika.schuetz@suchthilfe.at): no conflicts of interest. Cornelia Schwanke, Austria (cornelia.schwanke@suchthilfe.at): no conflicts of interest. Eva Krabb, Austria (eva.krabb@suchthilfe.at) no conflicts of interest. Raphael Schubert, Austria (raphael.schubert@outlook.at): received travel support from Gilead. Sophie-Therese Liebich, Austria (sophie-therese.liebich@suchthilfe.at): no conflicts of interest. David Bauer (david.bauer@meduniwien.ac.at): received travel support from Gilead and Abbvie and speaker fees from Abbvie. Lukas Burghart (lukas.burghart@gesundheitsverbund.at): no conflicts of interest. Leonard Brinkmann (leonard-ruben.brinkmann@gesundheitsverbund.at): no conflicts of interest. Enisa Gutic, Austria (enisa.gutic@extern.gesundheitsverbund.at): received travel support from Gilead and AbbVie. Thomas Reiberger, Austria (thomas.reiberger@meduniwien.ac.at): received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. Hans Haltmayer, Austria (hans.haltmayer@suchthilfe.at): no conflicts of interest. - Michael Gschwantler, Austria (michael.gschwantler@gesundheitsverbund.at): received grant support from Abbvie, Gilead and MSD; speaking honoraria from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Norgine, AstraZeneca, Falk, Shionogi, and MSD; consulting/advisory board fees from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Alnylam, Norgine, AstraZeneca, Falk, Shionogi and MSD; and travel support from Abbvie and Gilead.
- 3 November 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessCombining Treatment for Chronic Hepatitis C with Opioid Agonist Therapy is an Effective Microelimination Strategy for People Who Inject Drugs with High Risk of Non-Adherence to Antiviral Therapy
Background & Aims: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation. To overcome this, we combined ongoing opioid agonist therapy (OAT) with direct-acting antivirals (DAA) in a directly-observed therapy (DOT) setting. Method: From September 2014 until January 2021 PWIDs at high risk for non-adherence to DAA therapy were included in this microelimination project. PWIDs received HCV treatment alongside their OAT under supervision of healthcare workers in a pharmacy or low-threshold facility. Results: In total, 522 HCV-RNA-positive PWIDs (400 men, 76.6%; median age: 38 years [IQR 12], HIV: 4.4%; HBV: 1.3%) were included. Of these, 308/491 patients (62.7%) reported ongoing IDU (intravenous drug use). Following the concept of DOT, adherence to DAA treatment was excellent (missed appointments: 90/25,792, 0.4%). Forty-one (7.9%) patients were lost to follow-up. Two (0.4%) patients died due to reasons unrelated to DAA treatment. SVR12 was achieved in 457/461 (99.1%; 95% CI: 98.3-100.0%) patients, while only 4/461 (0.9%) patients showed treatment failure (modified intention-to-treat, mITT). Over a median follow-up of 24 (IQR 27) weeks, reinfections were observed in 27/457 (5.9%) patients. Conclusions: Coupling DAA treatment to OAT in a DOT setting resulted in SVR12 rates greater than 99% in PWIDs at high risk for non-adherence to therapy despite high rates of IDU. Importantly, only 7.9% of the patients were lost to follow-up, but finished DAA therapy. Competing Intrerest Statement: Michael Schwarz, Austria (schwarz.medizin@gmail.com): received speaking honoraria from BMS and travel support from BMS, AbbVie, Gilead, and MSD. - Caroline Schwarz, Austria (schwarz.caroline1990@gmail.com): received travel support from Gilead, Abbvie, and Gebro; speaking honoraria from Abbvie and Gilead; and served as a consultant for Gilead. Angelika Schütz, Austria (angelika.schuetz@suchthilfe.at): no conflicts of interest. Cornelia Schwanke, Austria (cornelia.schwanke@suchthilfe.at): no conflicts of interest. Eva Krabb, Austria (eva.krabb@suchthilfe.at) no conflicts of interest. Raphael Schubert, Austria (raphael.schubert@outlook.at): received travel support from Gilead. Sophie-Therese Liebich, Austria (sophie-therese.liebich@suchthilfe.at): no conflicts of interest. David Bauer (david.bauer@meduniwien.ac.at): received travel support from Gilead and Abbvie and speaker fees from Abbvie. Lukas Burghart (lukas.burghart@gesundheitsverbund.at): no conflicts of interest. Leonard Brinkmann (leonard-ruben.brinkmann@gesundheitsverbund.at): no conflicts of interest. Enisa Gutic, Austria (enisa.gutic@extern.gesundheitsverbund.at): received travel support from Gilead and AbbVie. Thomas Reiberger, Austria (thomas.reiberger@meduniwien.ac.at): received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. Hans Haltmayer, Austria (hans.haltmayer@suchthilfe.at): no conflicts of interest. - Michael Gschwantler, Austria (michael.gschwantler@gesundheitsverbund.at): received grant support from Abbvie, Gilead and MSD; speaking honoraria from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Norgine, AstraZeneca, Falk, Shionogi, and MSD; consulting/advisory board fees from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Alnylam, Norgine, AstraZeneca, Falk, Shionogi and MSD; and travel support from Abbvie and Gilead.
- 16 March 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (1) , 254-255
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis
- 16 March 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (1) , 254-255
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis